SMMT Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.…
Industry Peers
BiotechnologyKey Statistics
About Summit Therapeutics (NASDAQ: SMMT)
›
Summit Therapeutics (NASDAQ: SMMT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 265 employees.
The shares were at 10.57 USD on 19 November 2026, down 41.5% over 52 weeks. Its 52-week range is 10.14 USD to 29.23 USD: the price is 63.8% below the high and 4.2% above the low.
Its market capitalisation is 8.45B USD.
Summit Therapeutics reports return on equity of -163.9% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 609.81M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 13 analysts cover the stock, with an average rating of Buy; their mean price target of 28.94 USD is 173.8% above the current price. The next earnings report is expected on 22 February 2027.